|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8404 USD | -3.26% |
|
-11.32% | -81.32% |
| 07-07 | FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Phase 1/2 Diabetic Foot Ulcer Clinical Trial | CI |
| 06-29 | FibroBiologics Closes Private Placement | MT |
| Market Cap | 4.54M 3.97M 3.66M 3.39M 6.44M 431M 6.54M 43.88M 17.06M 213M 17.03M 16.67M 735M | P/E 2026 * |
-0.85x | P/E 2027 * | -0.39x |
|---|---|---|---|---|---|
| Enterprise Value | 4.54M 3.97M 3.66M 3.39M 6.44M 431M 6.54M 43.88M 17.06M 213M 17.03M 16.67M 735M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
87.38% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.26% | ||
| 1 week | -11.32% | ||
| Current month | -11.32% | ||
| 1 month | -18.41% | ||
| 3 months | -40.82% | ||
| 6 months | -87.78% | ||
| Current year | -81.32% |
| 1 week | 0.84 |  | 0.93 |
| 1 month | 0.73 | | 1.04 |
| Current year | 0.73 | | 9.6 |
| 1 year | 0.73 | | 14.68 |
| 3 years | 0.73 | | 1,100 |
| 5 years | 0.73 | | 1,100 |
| 10 years | 0.73 | | 1,100 |
| Manager | Title | Age | Since |
|---|---|---|---|
Peter O'Heeron
CEO | Chief Executive Officer | 62 | 07/04/2021 |
Jason Davis
DFI | Director of Finance/CFO | 53 | 08/06/2025 |
Hamid Khoja
CTO | Chief Tech/Sci/R&D Officer | 57 | 31/07/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 60 | 07/04/2021 |
Peter O'Heeron
CHM | Chairman | 62 | 07/04/2021 |
Matthew Link
BRD | Director/Board Member | 51 | 07/04/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-22 | Free | Director | 30,803 | 0.5914% | ||
| 06-22 | Free | Director | 30,803 | 0.5914% | ||
| 06-22 | Free | Director | 30,803 | 0.5914% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.26% | -11.32% | -93.05% | - | 4.54M | |
| -0.71% | +1.61% | +73.76% | +129.35% | 57.72B | |
| -3.80% | -6.24% | +67.04% | +86.36% | 52.65B | |
| +1.17% | +5.83% | +16.39% | +468.18% | 24.46B | |
| +0.38% | +1.33% | -14.32% | -11.76% | 23.84B | |
| -3.05% | +3.06% | +42.36% | -5.66% | 19.28B | |
| -0.54% | +5.04% | +44.15% | -26.66% | 17.8B | |
| +3.46% | +17.72% | +206.66% | +364.07% | 17.29B | |
| -6.73% | +9.90% | +36.04% | - | 15.28B | |
| +2.79% | +4.91% | +29.26% | +195.60% | 14.35B | |
| Average | -1.03% | +3.51% | +40.83% | +149.93% | 24.27B | |
| Weighted average by Cap. | -1.13% | +2.58% | +57.66% | +139.40% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -20.36M -17.81M -16.42M -15.22M -28.89M -1.93B -29.35M -197M -76.56M -954M -76.43M -74.77M -3.3B | -24.01M -21.01M -19.37M -17.95M -34.07M -2.28B -34.62M -232M -90.3M -1.12B -90.15M -88.2M -3.89B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/07/26 | US$0.8404 | -3.26% | 46,682 |
| 06/07/26 | US$0.8687 | -0.78% | 59,184 |
| 02/07/26 | US$0.8755 | -3.40% | 59,071 |
| 01/07/26 | US$0.9063 | -4.37% | 106,928 |
| 30/06/26 | US$0.9477 | +19.22% | 268,908 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- FBLG Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
